DK1891038T3 - Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer - Google Patents
Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorerInfo
- Publication number
- DK1891038T3 DK1891038T3 DK06759481T DK06759481T DK1891038T3 DK 1891038 T3 DK1891038 T3 DK 1891038T3 DK 06759481 T DK06759481 T DK 06759481T DK 06759481 T DK06759481 T DK 06759481T DK 1891038 T3 DK1891038 T3 DK 1891038T3
- Authority
- DK
- Denmark
- Prior art keywords
- arylpyrrolidines
- substituted
- androgen receptor
- compound
- formula
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68091105P | 2005-05-13 | 2005-05-13 | |
| PCT/US2006/018061 WO2006124447A2 (en) | 2005-05-13 | 2006-05-10 | Substituted n-arylpyrrolidines as selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1891038T3 true DK1891038T3 (da) | 2009-01-19 |
Family
ID=37057376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06759481T DK1891038T3 (da) | 2005-05-13 | 2006-05-10 | Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7807691B2 (enExample) |
| EP (1) | EP1891038B1 (enExample) |
| JP (1) | JP5089578B2 (enExample) |
| CN (1) | CN101175747B (enExample) |
| AT (1) | ATE412647T1 (enExample) |
| AU (1) | AU2006247738A1 (enExample) |
| BR (1) | BRPI0610183A2 (enExample) |
| CA (1) | CA2608419A1 (enExample) |
| CY (1) | CY1108690T1 (enExample) |
| DE (1) | DE602006003432D1 (enExample) |
| DK (1) | DK1891038T3 (enExample) |
| ES (1) | ES2314922T3 (enExample) |
| MX (1) | MX2007014053A (enExample) |
| PL (1) | PL1891038T3 (enExample) |
| PT (1) | PT1891038E (enExample) |
| SI (1) | SI1891038T1 (enExample) |
| WO (1) | WO2006124447A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5070054B2 (ja) * | 2005-08-01 | 2012-11-07 | 武田薬品工業株式会社 | 環状アミン化合物 |
| JP5241507B2 (ja) | 2006-11-30 | 2013-07-17 | 武田薬品工業株式会社 | 環状アミン化合物 |
| TW200831080A (en) * | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| AR067823A1 (es) | 2007-08-07 | 2009-10-21 | Takeda Pharmaceutical | Compuestos de amina ciclica |
| CA2709677C (en) | 2007-12-21 | 2017-03-14 | Lin Zhi | Selective androgen receptor modulators (sarms) and uses thereof |
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| MX2010009162A (es) | 2008-02-22 | 2010-12-21 | Radius Health Inc | Moduladores selectivos del receptor de androgeno. |
| WO2009131196A1 (ja) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | 置換ピロリジン誘導体およびその用途 |
| WO2009133861A1 (ja) * | 2008-04-28 | 2009-11-05 | 武田薬品工業株式会社 | 環状アミン化合物 |
| EP2531029B1 (en) | 2010-02-04 | 2016-10-19 | Radius Health, Inc. | Selective androgen receptor modulators |
| US20130053448A1 (en) | 2010-05-12 | 2013-02-28 | Louis O'Dea | Therapeutic Regimens |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| SG192795A1 (en) * | 2011-02-25 | 2013-09-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| HK1212235A1 (en) * | 2012-11-16 | 2016-06-10 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
| CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| MX389702B (es) | 2016-06-22 | 2025-03-20 | Ellipses Pharma Ltd | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). |
| US10385008B2 (en) | 2017-01-05 | 2019-08-20 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD1901-2HCL |
| CA3072362A1 (en) | 2017-10-06 | 2019-04-11 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| WO2019222272A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| SG11202011299PA (en) | 2018-05-17 | 2020-12-30 | Forma Therapeutics Inc | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| KR102792490B1 (ko) | 2018-07-04 | 2025-04-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| MY209034A (en) | 2018-10-05 | 2025-06-17 | Forma Therapeutics Inc | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
| CN113348163B (zh) | 2019-02-12 | 2024-10-08 | 雷迪厄斯制药公司 | 方法和化合物 |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020232119A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2021098810A1 (zh) * | 2019-11-20 | 2021-05-27 | 南京明德新药研发有限公司 | 用作选择性雄激素受体调节剂的化合物 |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| IL308104A (en) | 2021-05-03 | 2023-12-01 | Nuvation Bio Inc | Nuclear hormone receptor-targeted compounds against cancer |
| WO2025160286A1 (en) * | 2024-01-24 | 2025-07-31 | Siteone Therapeutics, Inc. | 2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| FR2671348B1 (fr) * | 1991-01-09 | 1993-03-26 | Roussel Uclaf | Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| US5411981A (en) * | 1991-01-09 | 1995-05-02 | Roussel Uclaf | Phenylimidazolidines having antiandrogenic activity |
| US6887870B1 (en) | 1999-10-12 | 2005-05-03 | Bristol-Myers Squibb Company | Heterocyclic sodium/proton exchange inhibitors and method |
| WO2004016576A1 (ja) | 2002-08-12 | 2004-02-26 | Takeda Pharmaceutical Company Limited | 縮合ベンゼン誘導体および用途 |
| WO2004037784A2 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Pyrrolidones with anti-hiv activity |
| US20060148893A1 (en) * | 2003-06-10 | 2006-07-06 | Blanc Jean-Baptiste E | Chemical compounds |
-
2006
- 2006-05-10 WO PCT/US2006/018061 patent/WO2006124447A2/en not_active Ceased
- 2006-05-10 ES ES06759481T patent/ES2314922T3/es active Active
- 2006-05-10 CN CN2006800165544A patent/CN101175747B/zh not_active Expired - Fee Related
- 2006-05-10 MX MX2007014053A patent/MX2007014053A/es active IP Right Grant
- 2006-05-10 EP EP06759481A patent/EP1891038B1/en not_active Not-in-force
- 2006-05-10 JP JP2008511312A patent/JP5089578B2/ja not_active Expired - Fee Related
- 2006-05-10 BR BRPI0610183-6A patent/BRPI0610183A2/pt not_active IP Right Cessation
- 2006-05-10 DK DK06759481T patent/DK1891038T3/da active
- 2006-05-10 CA CA002608419A patent/CA2608419A1/en not_active Abandoned
- 2006-05-10 PL PL06759481T patent/PL1891038T3/pl unknown
- 2006-05-10 AU AU2006247738A patent/AU2006247738A1/en not_active Abandoned
- 2006-05-10 US US11/913,710 patent/US7807691B2/en not_active Expired - Fee Related
- 2006-05-10 SI SI200630177T patent/SI1891038T1/sl unknown
- 2006-05-10 AT AT06759481T patent/ATE412647T1/de active
- 2006-05-10 PT PT06759481T patent/PT1891038E/pt unknown
- 2006-05-10 DE DE602006003432T patent/DE602006003432D1/de active Active
-
2009
- 2009-01-09 CY CY20091100016T patent/CY1108690T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1891038B1 (en) | 2008-10-29 |
| PT1891038E (pt) | 2008-12-02 |
| WO2006124447A3 (en) | 2007-03-29 |
| MX2007014053A (es) | 2008-02-05 |
| PL1891038T3 (pl) | 2009-04-30 |
| CY1108690T1 (el) | 2014-04-09 |
| JP5089578B2 (ja) | 2012-12-05 |
| SI1891038T1 (sl) | 2009-04-30 |
| DE602006003432D1 (de) | 2008-12-11 |
| CN101175747B (zh) | 2011-06-22 |
| US20080176864A1 (en) | 2008-07-24 |
| JP2008540554A (ja) | 2008-11-20 |
| EP1891038A2 (en) | 2008-02-27 |
| ATE412647T1 (de) | 2008-11-15 |
| BRPI0610183A2 (pt) | 2012-12-04 |
| CN101175747A (zh) | 2008-05-07 |
| CA2608419A1 (en) | 2006-11-23 |
| ES2314922T3 (es) | 2009-03-16 |
| WO2006124447A2 (en) | 2006-11-23 |
| AU2006247738A1 (en) | 2006-11-23 |
| US7807691B2 (en) | 2010-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108690T1 (el) | Υποκατεστημενες ν-αρυλοπυρρολιδινες ως επιλεκτικοι διαμορφωτες υποδοχεα ανδρογονων | |
| DE602006012322D1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| EA200970500A1 (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ | |
| EA201071317A1 (ru) | ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛЬНЫЕ МОДУЛЯТОРЫ РЕЦЕПТОРОВ АНДРОГЕНОВ | |
| EA201491607A1 (ru) | Модуляторы толлподобных рецепторов | |
| EA200970913A1 (ru) | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
| DE602006006712D1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| TW200626158A (en) | Naphthaline derivatives | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| EA200802000A1 (ru) | Фармацевтически приемлемые соли и полиморфные формы | |
| DOP2009000117A (es) | Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos | |
| UA93951C2 (ru) | Производные 2-пиридинкарбоксамида b качестве модуляторов натриевых каналов |